Schroder Investment Management Group Sells 86,092 Shares of Vera Therapeutics, Inc. $VERA

Schroder Investment Management Group lessened its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 18.8% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 372,749 shares of the company’s stock after selling 86,092 shares during the period. Schroder Investment Management Group’s holdings in Vera Therapeutics were worth $8,782,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in VERA. Quarry LP boosted its stake in shares of Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after purchasing an additional 500 shares during the period. AlphaQuest LLC lifted its holdings in Vera Therapeutics by 404.7% during the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after buying an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in Vera Therapeutics by 14.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after buying an additional 539 shares in the last quarter. Fifth Third Bancorp purchased a new stake in Vera Therapeutics in the 2nd quarter valued at about $102,000. Finally, Ameritas Investment Partners Inc. grew its stake in Vera Therapeutics by 13.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock worth $124,000 after acquiring an additional 615 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA opened at $42.61 on Friday. The firm has a 50 day moving average of $30.04 and a 200 day moving average of $25.29. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of -10.68 and a beta of 1.21. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $49.77.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter last year, the firm posted ($0.85) earnings per share. On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VERA. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a report on Friday, November 28th. Finally, Bank of America initiated coverage on Vera Therapeutics in a research report on Thursday, October 16th. They set a “buy” rating and a $48.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.00.

Insider Buying and Selling

In other Vera Therapeutics news, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total transaction of $435,900.00. Following the completion of the sale, the senior vice president directly owned 47,839 shares of the company’s stock, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 16.30% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.